KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Q3 2025 value amounting to -$12.8 million.

  • Supernus Pharmaceuticals' Tax Provisions fell 29914.68% to -$12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 11300.47%. This contributed to the annual value of $24.0 million for FY2024, which is 155209.91% up from last year.
  • Supernus Pharmaceuticals' Tax Provisions amounted to -$12.8 million in Q3 2025, which was down 29914.68% from -$5.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Tax Provisions high stood at $25.9 million for Q3 2023, and its period low was -$16.3 million during Q2 2023.
  • Moreover, its 5-year median value for Tax Provisions was $3.5 million (2022), whereas its average is $1.7 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Tax Provisions plummeted by 56571.43% in 2023 and then surged by 604864.86% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Tax Provisions stood at -$391000.0 in 2021, then skyrocketed by 2570.33% to $9.7 million in 2022, then tumbled by 101.92% to -$185000.0 in 2023, then skyrocketed by 6048.65% to $11.0 million in 2024, then plummeted by 216.65% to -$12.8 million in 2025.
  • Its Tax Provisions stands at -$12.8 million for Q3 2025, versus -$5.8 million for Q2 2025 and $6.0 million for Q1 2025.